doi: 10.1016/j.cell.2023.05.003
[33, 34, 35, 36] Mechanism: Typically pre-renal, occurring in the setting of volume depletion from GI losses (nausea, vomiting, diarrhea, reduced oral intake) More frequently seen at higher, obesity-level doses Although generally reno-protective long term, post-marketing data describe acute rises in creatinine following days to weeks of significant GI symptoms Risk factors: Underlying chronic kidney disease Concomitant use of ACE inhibitors, ARBs, diuretics, or SGLT2 inhibitors ED Management: IV fluids Hold GLP-1 and contributing medications Usually reversible with supportive care Future Directions GLP-1 receptor agonists are rapidly evolving beyond their original indications in diabetes and obesity
Wegovy and Saxenda are effective alternatives, with different dosing and results
The best medication is not always the one with the biggest average result in a study
[DOI] [PubMed] [Google Scholar] 3.Platkiewicz J., Okolowicz D., Frankowski R., Grzeskowiak T., Jeszka-Skowron M., Zgola-Grzeskowiak A